155 related articles for article (PubMed ID: 20064151)
1. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Scott BL; Ramakrishnan A; Storer B; Becker PS; Petersdorf S; Estey EH; Deeg HJ
Br J Haematol; 2010 Mar; 148(6):944-7. PubMed ID: 20064151
[TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
5. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
Almeida AM; Pierdomenico F
Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
[No Abstract] [Full Text] [Related]
6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
[TBL] [Abstract][Full Text] [Related]
7. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
8. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
9. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
10. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
11. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
14. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
15. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Kobayashi Y; Munakata W; Ogura M; Uchida T; Taniwaki M; Kobayashi T; Shimada F; Yonemura M; Matsuoka F; Tajima T; Yakushijin K; Minami H
Int J Hematol; 2018 Jan; 107(1):83-91. PubMed ID: 28905323
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
[TBL] [Abstract][Full Text] [Related]
18. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
[TBL] [Abstract][Full Text] [Related]
19. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
20. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
